Ann: Unusual Trading Patterns, page-22

I personally believe stock will continue on pathway until there is a complete renewal of management (and probably board too). It is scary how many failed strategies/promises this stock has been associated in last few years.

been such a lesson for me, that I kind of want to keep it as a regular reminder of not getting sucked in by management who are all sales with no realisable pathway for growth. it is a smoke & mirror stock, and I believe this latest share price manipulation hype is just another distraction from accountability. this investigation will cost the company money and at the end of the day will not achieve a single tangible thing. Will be surprised if anyone is charged or there are any consequences. but it puts out a distraction for discussion, when the real discussion is whether the time for change is now.

my memory of this stock is
- SP is 95% what it used to be when current management started....to tell the truth can even calculate it because every 18 months the shares are consolidated on a 10-1 basis (is a 10-1 consolidation a method to distract from poor performance?)
- CEO salary has increase substantially over a period of substantial SP depreciation
- business has been up rooted to America away from manufacturers basis where CEO lives...on basis this will be good for networking...has there been any evidence of company benefiting from good networking? not aware of any deal that didn't involve selling key assets. could be wrong.
- CEO has hired former work colleges contacts on high salaries and with high expectations - have they delivered? have CEO and old work college crew been hitting performance bonuses? haven't looked but wouldn't be surprised if they had.
- business has lived off selling assets (sold part of vaccine business; sold a profitable medical supplies business; sold the much hyped cardiocel) and capital raising (a lot has been raised in the past). if you want to be in the milk business don't sell all your cows.
- management biggest success has been selling "growth is around the corner" to the shareholder base. maybe management is more talented at sales than managing an ASX company and they should be freed up to go back to there true calling.
- why was the name of company changed? surely not to distance/distract from past performance. so why?

reality is if ADMEDUS (as it used to be called) in 2015 sought to sell cardiocel through reputable and established international medical distributors rather than setting up own USA and European sales team then the company would have been a monster by now. paradoxically ADMEDUS old medical supply business was based on this model.